In this issue:
Ambroxol for PD with and without GBA mutations
Nilotinib effects on safety, tolerability and potential biomarkers in PD
Association between antiviral therapy and PD risk in chronic HCV infection
Sublingual apomorphine for ‘off’ episodes in PD
Home-based, remotely supervised aerobic exercise in PD
WMH burden and cognitive impairment in early PD
5-hydroxytryptophan for depression/apathy in PD
Melatonin ineffective for REM sleep behaviour disorder in PD
DBS for FOG in PD with early motor complications
Please login below to download this issue (PDF)